2013年から2021年までの,多発性硬化症の疾患修正治療のリストおよび純価格の変化

Daniel M Hartung¹, Nico Gabriel², Walid F Gellad³

¹Pharmacy Practice, Oregon State University.

Neurology. Clinical practice

|February 19, 2026

まとめ

口腔多発性硬化症 (MS) 疾患修飾療法 (DMT) の純価格は,割引によるリスト価格より少なく上昇した. モノクローナル抗体 (MAb) DMTの純価格は著しく上昇し,割引は価格上昇を相殺した.

科学分野:

医薬品の価格分析について
医療経済学とは
多発性硬化症の治療薬について

背景:

多発性硬化症 (MS) は,中枢神経系に影響を与える慢性自己免疫疾患です.
疾患修正療法 (DMT) は,MSの進行を管理する上で極めて重要です.
薬の価格の動向を理解することは,患者のアクセスと医療の持続可能性にとって不可欠です.

研究の目的:

2013年から2021年までのブランドMS DMTのリストおよび純価格の変化を分析する.
経口DMTとモノクローナル抗体 (MAb) DMTの価格動向を比較する.
医薬品の純価格に対する製造者割引の影響を評価する.

主な方法:

利用された医薬品の価格と利用データソース.
ブランド口腔およびMAb DMTの推定リストおよび純価格.
計算されたインフレ調整価格,年間平均変動 (AAC),割引率.

主要な成果:

口服用DMTのリスト価格はAAC5.3%上昇し,純価格はAAC1.5%上昇した.これは,割引の増加 (6.4%-21.2%) に起因した.
MAb DMTのリスト価格はAAC4.1%上昇し,純価格はAAC3.0%上昇した.
割引は,口服用DMTの累積的なリスト価格上昇の51%~86%を相殺し,MAb DMTの0%~35%を相殺した.

結論:

異なる純価格の動向は,口服DMT間の競争の増大を示唆している.
バイオシミラーオプションの欠如は,MAb DMTsの純価格の増加に寄与する可能性があります.
製造者による割引は,MSの治療薬の純価格の上昇を緩和する上で重要な役割を果たしています.

さらに関連する動画

10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K

08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.9K

関連する概念動画

01:26

FDA Approved Drugs: Changes to Approved Drugs

286

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

286

01:29

Therapeutic Drug Monitoring: Affecting Factors

258

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

258

01:28

Drug Products: Biologics, Biosimilars and Interchangeables

288

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

288

01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

574

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

574

01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...

01:22

Alzheimer's Disease: Treatment

1.0K

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...